Select Page

PsychoGenics CEO explores CNS drug development trends

PsychoGenics CEO explores CNS drug development trends February 4, 2023 · By Brian Buntz · Drug Discovery & Development In the late 2000s, many companies, particularly Big Pharma, exited the field of central nervous system (CNS) drug development and, particularly...

Why the TAAR1 agonist ulotaront holds promise for schizophrenia

Why the TAAR1 agonist ulotaront holds promise for schizophrenia November 22, 2022 · By Brian Buntz · Drug Discovery & Development Ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist in Phase 3 clinical development, could prove to be a...